SCHEMBL794440

SCHEMBL794440

CCNc1ccc(F)c(Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.57
CYP3A4 P08684 2/20 0.57
CYP2C9 P11712 2/20 0.57
CYP2C19 P33261 2/20 0.57
PLA2G1B P04054 1/20 0.57
CYP1A2 P05177 1/20 0.57
CYP2D6 P10635 1/20 0.57
ATG4B Q9Y4P1 1/20 0.57
MEN1 O00255 6/20 0.52
KMT2A Q03164 6/20 0.52
MAPT P10636 6/20 0.52
HTT P42858 3/20 0.52
ALDH1A1 P00352 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
SMN1; SMN2 Q16637 3/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
RAPGEF4 Q8WZA2 1/20 0.50
IDO1 P14902 1/20 0.49
TDO2 P48775 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30597995 1.00 TSHR (0.57) TSHRCYP3A4CYP2C9CYP2C19PLA2G1B
Hydrochloric Acid SCHEMBL3395744 0.98 TSHR (0.56) TSHRCYP3A4CYP2C9CYP2C19PLA2G1B
SCHEMBL28294737 0.86 PLA2G1B (0.59) TSHRCYP3A4CYP2C9CYP2C19PLA2G1B
SCHEMBL11526512 0.85 CYP3A4 (0.62) TSHRCYP3A4CYP2C9CYP2C19PLA2G1B
SCHEMBL3397984 0.84 RAPGEF4 (0.50) TSHRCYP3A4CYP2C9CYP2C19PLA2G1B
SCHEMBL27511192 0.83 ABL1 (0.55) TSHRCYP3A4CYP2C9CYP2C19PLA2G1B
Hydrochloric Acid SCHEMBL3395950 0.82 RAPGEF4 (0.49) TSHRCYP3A4CYP2C9CYP2C19PLA2G1B
SCHEMBL29659123 0.81 MAPT (0.46) TSHRCYP3A4CYP2C9CYP2C19PLA2G1B
SCHEMBL631579 0.81 MAPT (0.46) TSHRCYP3A4CYP2C9CYP2C19PLA2G1B
SCHEMBL1799567 0.81 CYP3A4 (0.53) CYP3A4MEN1KMT2AMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528595-B1 COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES INOXIA LIFESCIENCES GMBH (AT) 2015-08-05 EP claimed
US-20110053985-A1 NOVEL PIPERIDINE-4-CARBOXYLIC ACID PHENYL-ALKYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2011-03-03 US claimed
EP-2245011-A1 NOVEL PIPERIDINE-4-CARBOXYLIC ACID PHENYL-ALKYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2010-11-03 EP claimed
WO-2009090173-A1 NOVEL PIPERIDINE-4-CARBOXYLIC ACID PHENYL-ALKYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2009-07-23 WO claimed
US-20250325547-A1 ANTI-SARS-COV-2 DRUG KAGOSHIMA UNIVERSITY (JP) 2025-10-23 US disclosed
US-12358886-B2 Heterocyclic compounds for use in the treatment of cancer ARTIOS PHARMA LIMITED (GB) 2025-07-15 US disclosed
WO-2025016138-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF SUZHOU EOC MEDICAL RESEARCH CO., LTD. (CN) 2025-01-23 WO disclosed
CN-114667167-B Heterocyclic compounds for the treatment of cancer 阿提奥斯医药有限公司 2024-12-20 CN disclosed
EP-4431151-A1 ANTI-SARS-COV-2 DRUG Kagoshima University (JP) 2024-09-18 EP disclosed
CN-118302413-A Anti-SARS-CoV-2 medicine 国立大学法人鹿儿岛大学 2024-07-05 CN disclosed
US-20230322715-A1 BROAD SPECTRUM ANTI-CANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-10-12 US disclosed
EP-4010080-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LTD (GB) 2023-09-27 EP disclosed
EP-2245011-A1 NOVEL PIPERIDINE-4-CARBOXYLIC ACID PHENYL-ALKYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2010-11-03 EP disclosed
US-20100113452-A1 COMPOUNDS FOR TREATING PULMONARY HYPERTENSION BAYER HEALTHCARE AG (DE) 2010-05-06 US disclosed
WO-2009090173-A1 NOVEL PIPERIDINE-4-CARBOXYLIC ACID PHENYL-ALKYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2009-07-23 WO disclosed
CN-1256328-C Position seven substituted amine methyl fluoro quinolone derivative having antibacterial activity and its preparation method SHANGHAI INST PHARM INDUSTRY (CN) 2006-05-17 CN disclosed
CN-1493562-A Position seven substituted amine methyl fluoro quinolone derivative having antibacterial activity and its preparation method 上海医药工业研究院 2004-05-05 CN disclosed
CN-1303389-A 3 ', 3' -N-disubstituted macrolide Luteinizing Hormone Releasing Hormone (LHRH) antagonists ABBOTT LAB (US) 2001-07-11 CN disclosed
US-5283248-A Bactericides, enzyme inhibitor of DNA-gyrase in bacteria HOFFMANN-LA ROCHE INC. (US) 1994-02-01 US disclosed
EP-0433648-A1 Substituted pyrimidobenzimidazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 1991-06-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053985-A1 NOVEL PIPERIDINE-4-CARBOXYLIC ACID PHENYL-ALKYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS SLC18A2, SLC6A2, SLC18A3 TSHR 1152/4885CYP3A4 510/4885CYP2C9 627/4885
US-20100113452-A1 COMPOUNDS FOR TREATING PULMONARY HYPERTENSION PTGIR, PTGIS, EDNRB TSHR 2041/4885CYP3A4 2340/4885CYP2C9 3227/4885
US-20230322715-A1 BROAD SPECTRUM ANTI-CANCER COMPOUNDS YTHDF1, YTHDF3, YTHDF2 TSHR 2302/4885CYP3A4 4503/4885CYP2C9 4535/4885
US-20250325547-A1 ANTI-SARS-COV-2 DRUG ACE2, ACE, AGTR2 TSHR 27/4885CYP3A4 529/4885CYP2C9 823/4885
US-12358886-B2 Heterocyclic compounds for use in the treatment of cancer SDHA, DPYD, TP53 TSHR 3750/4885CYP3A4 70/4885CYP2C9 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.